|
Nephroblastoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Prognostic significance of The Wilms' Tumor-1 (WT1) rs16754 polymorphism in acute myeloid leukemia.
|
29407184 |
2018 |
|
Nephroblastoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
WAGR (Wilms tumor, Aniridia, Genitourinary malformations and mental Retardation) syndrome is a rare genomic disorder caused by deletion of the 11p14-p12 chromosome region.
|
19096215 |
2008 |
|
Nephroblastoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Quantitative analysis of WT1 gene expression (bone marrow samples) was available in all cases both at diagnosis (100% of samples overexpressed WT1 with a mean of 8607±8187 copies/10<sup>4</sup> Abelson) and immediately before allo-SCT.
|
29096332 |
2017 |
|
Nephroblastoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
In this study, mIDH1R132H immunoreactivity in 120 reactive gliosis specimens of various etiologies is compared with Wilms Tumor 1 (WT1) and p53 expression, both markers applied for the differentiation of reactive gliosis and glioma.
|
20661018 |
2010 |
|
Nephroblastoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Wilms' tumor 1 (WT1) is constantly expressed in leukemic cells of acute leukemia and myelodysplastic syndrome (MDS).
|
28860210 |
2017 |
|
Nephroblastoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Two eSTS markers have been further mapped with respect to a yeast artificial chromosome (YAC) contig close to the brain-derived neurotrophic factor (BDNF) gene and thus provide potential candidate genes for the mental retardation phenotype of WAGR (Wilms' tumor, aniridia, genitourinary abnormalities and mental retardation) syndrome.
|
8717056 |
1995 |
|
Nephroblastoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Although the majority of congenital urogenital abnormalities are not due to constitutional defects of the WT1 gene, our findings provide a rational for considering WT1 mutational analysis as one of the screening options in newborns with congenital defects of the urogenital tract due to the associated high risk of WT.
|
19048299 |
2009 |
|
Nephroblastoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
The oncogenic role of Wilms' tumor 1 (WT1) which is regarded as a promising target antigen for cancer immunotherapy has been demonstrated in many types of cancer, but the relationship between expression of WT1 and the prognosis value in gynecological cancer reminds unclear.We performed a meta-analysis with thirteen published studies including 2205 patients searched from PubMed, EMBASE, Web of Science, and Google Scholar, whose results are expressed by overall survival (OS) or disease-specific survival (DSS) or disease-free survival or relapse/recurrence-free survival (RFS) or progression-free survival (PFS) in patients with gynecological cancer.
|
29995811 |
2018 |
|
Nephroblastoma
|
0.800 |
GeneticVariation
|
disease |
UNIPROT |
The detection of one nonsense point mutation and one missense WT1 gene point mutation adds to the accumulating evidence implicating this gene in a proportion of Wilms tumor patients.
|
1317572 |
1992 |
|
Nephroblastoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A point mutation found in the WT1 gene in a sporadic Wilms' tumor without genitourinary abnormalities is identical with the most frequent point mutation in Denys-Drash syndrome.
|
8381368 |
1993 |
|
Nephroblastoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Wilms' tumor 1 (WT1) is well known as a pan-leukemic marker.
|
28673850 |
2017 |
|
Nephroblastoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
SHMT1 promoter analysis identified transcription factor Wilms tumor 1 (WT1) binding sites, and WT1 knockdown resulted in reduced SHMT1 transcription in ovarian cancer cells.
|
28288142 |
2017 |
|
Nephroblastoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Six eligible PDA patients underwent multimodal therapy comprising dendritic cells (DCs) pulsed with Wilms' tumor 1 (WT1) peptide (DC/WT1-I) restricted by the human leukocyte antigen (HLA) class I (A*24:02 or A*02:06) allele, chemotherapy, radiation, and/or surgery.
|
30230959 |
2019 |
|
Nephroblastoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Ectopic miR-193a overexpression inhibited the proliferation, colony formation, migration, and invasion of MDA-MB-231 and BT549 cells. miR-193a reduced Wilms' tumor 1 (WT1) expression and repressed luciferase reporter activity by binding WT1 coding region sequences; mutation of the predicted miR-193a binding site abolished this effect. miR-193a and WT1 expression were significantly inversely correlated in breast cancer tissues.
|
29016617 |
2017 |
|
Nephroblastoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The remaining four had chromosomal rearrangements: an unbalanced translocation, t(11;13), with a deletion including the WAGR (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation) region, and three balanced rearrangements with what appear to be position effect breakpoints 3' of PAX6: (a) a t(7;11) with the 11p13 breakpoint approximately 30 kb downstream of PAX6, (b) a dir ins(12;11) with a breakpoint >50 kb from PAX6, and (c) an inv(11)(p13q13) with a breakpoint >75 kb downstream of PAX6.
|
12386836 |
2002 |
|
Nephroblastoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
The WT1 gene is normally expressed in fetal kidney and mesothelium, and its expression has been suggested as a marker for Wilms tumor and mesothelioma.
|
9841704 |
1999 |
|
Nephroblastoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
In the same way, the expression for Wilms tumor 1 (WT1) has only been studied occasionally in the endothelial cells of glomovenous malformations and in the glomus cells of glomus tumours.
|
27184662 |
2017 |
|
Nephroblastoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We have now investigated whether mutations in the WT1 promoter could be associated with loss of control WT1 expression and subsequent Wilms tumour formation.
|
7731725 |
1995 |
|
Nephroblastoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The WAGR contiguous gene deletion syndrome is a combination of Wilms tumor, aniridia, genito-urinary abnormalities, and mental retardation.
|
21660403 |
2011 |
|
Nephroblastoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Desmoplastic small round cell tumors (DSRCTs) present a reciprocal chromosomal translocation, t(11;22)(p13;q12), that results in fusion of Ewing's sarcoma and Wilms' tumor (WT1) genes.
|
10843285 |
2000 |
|
Nephroblastoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We report here that a patient with relapsed MDS after allo-BMT was successfully treated by the rapid discontinuation of immunosuppressive therapy at molecular relapse while monitoring Wilms tumor (WT1) gene expression levels.
|
16432864 |
2006 |
|
Nephroblastoma
|
0.800 |
Biomarker
|
disease |
HPO |
|
|
|
|
Nephroblastoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Taken together, these results suggest that GATA-1 and/or GATA-2 binding to a GATA site of the 3' enhancer of WT1 played an important role in WT1 gene expression.
|
19212333 |
2009 |
|
Nephroblastoma
|
0.800 |
CausalMutation
|
disease |
CLINVAR |
Genetic screening in adolescents with steroid-resistant nephrotic syndrome.
|
23515051 |
2013 |
|
Nephroblastoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
No gross genomic changes of the Wilms' tumor 1 (WT1) tumor suppressor gene were found using a cDNA probe (WT33).
|
7515656 |
1994 |